Rheumatoid Arthritis and Medical Cannabis: A Patient’s Guide

Why Cannabis May Help in Rheumatoid Arthritis

• Rheumatoid arthritis (RA) is characterised by autoimmune-driven joint inflammation, pain, and progressive structural damage
• CBD and THC both exert anti-inflammatory effects by modulating cytokine production and immune cell activity via CB2 receptors
• Preclinical studies in murine arthritis models show that cannabinoids reduce joint swelling, cartilage degradation, and bone erosion
• The analgesic properties of cannabis complement its anti-inflammatory actions, addressing both pain and its underlying driver

Rheumatoid arthritis affects approximately 400,000 people in the UK and remains a condition with significant unmet need, particularly for patients with persistent pain despite disease-modifying therapy.

What the Clinical Evidence Shows

• A 2006 RCT of Sativex in RA patients demonstrated significant improvements in pain on movement, pain at rest, and sleep quality
• Observational studies from UK and Canadian patient registries show high rates of self-reported benefit in RA and related inflammatory arthritides
• CBD appears to reduce TNF-alpha production, a key inflammatory mediator and the target of biologic therapies in RA
• Survey data suggest that many RA patients already use over-the-counter CBD products, highlighting a clear unmet demand for prescribed options

The clinical evidence for cannabis in RA is modest but growing, with the 2006 Sativex trial providing the most robust data to date and newer studies beginning to fill the evidence gap.

Getting a Prescription for RA in the UK

• A rheumatologist or specialist pain physician can prescribe cannabis-based medicines for RA under Schedule 2
• Patients should document inadequate response or intolerance to at least two conventional DMARDs before requesting a cannabis assessment
• Private prescribing clinics can often provide faster access than NHS pathways, though costs must be weighed carefully
• CBD-dominant products are typically tried first for their anti-inflammatory profile with lower psychoactive risk

Patients with active RA who have not achieved adequate disease control should raise medical cannabis as a potential option with their rheumatologist or consider a referral to a specialist cannabis clinic.

Practical Considerations for RA Patients

• Joint inflammation and hand dysfunction may make some administration methods (e.g., rolling, vaporising) practically difficult
• Oil tinctures and capsules are generally the most convenient formulations for patients with significant joint disease
• Cannabis does not replace disease-modifying therapy; it should be considered an adjunct for symptom management, not a curative treatment
• Monitoring should include pain scores, functional assessments, and screening for mood changes or dependency risk

When integrated thoughtfully into a broader treatment plan, medical cannabis can help RA patients achieve better pain control and improved quality of life alongside their established rheumatological care.